现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • Doxorubicin(Adriamycin;游离阿霉素)的结构
Doxorubicin(Adriamycin;游离阿霉素)的可视化放大

Doxorubicin(Adriamycin;游离阿霉素)

原价
¥750.00-1875.00
价格
350.00-1000.00
Doxorubicin(Adriamycin;游离阿霉素)的二维码

所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

可选包装 >>>
首页

Topo II inhibitor,immunosuppresive antineoplastic antibiotic

货号:ajci18230
CAS:23214-92-8
分子式:C27H29NO11
分子量:543.52
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.


Doxorubicin intercalates into DNA double strand and inhibits the progression of DNA topoisomerase II, stopping replication process. [2] Doxorubicin also induces histone eviction from open chromatin, causing DNA damage and epigenetic deregulation. [3]


Doxorubicin is administrated intravenously. Approximately 75% of doxorubicin and its metabolites bind to plasma protein. Doxorubicin does not cross blood brain barrier. 50% of the drug is eliminated unchanged from the body mainly though bile excretion. The remaining undergoes one-electron reduction, two-electron reduction, and deglycosidation. The major metabolite is a potent membrane ion pump inhibitor, which is associated with cardiomyopathy. [4]


参考文献:
[1]Brayfield, A, ed. (2013). Doxorubicin. Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
[2]Pommier Y., et al. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology 17 (5): 421–433.
[3]Pang, B., et al. (2013). Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications 4 (5): 1908
[4]Boucek RJ., et al. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of car
diac muscle with isolated membrane fractions. J of Biol Chem 262: 15851-15856.


恭喜以下科学家使用Amgicam的此产品研究取得重大突破:

1.Zhicheng Wang,Chao Sun,Haijun Wu, et al.Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer.sciencedirect.j.mtbio.2021.100189

产品引用

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服